Reviewing Audentes Therapeutics Inc. (BOLD)’s and OncoCyte Corporation (NYSEAMERICAN:OCX)’s results

Audentes Therapeutics Inc. (NASDAQ:BOLD) and OncoCyte Corporation (NYSEAMERICAN:OCX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. 28 -0.52 37.36M -3.79 0.00
OncoCyte Corporation 2 0.00 18.08M -0.38 0.00

Table 1 demonstrates Audentes Therapeutics Inc. and OncoCyte Corporation’s top-line revenue, earnings per share and valuation.


Table 2 demonstrates the net margins, return on equity and return on assets of Audentes Therapeutics Inc. and OncoCyte Corporation.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 135,706,502.00% -40.8% -37.4%
OncoCyte Corporation 1,074,335,967.67% -113.2% -83%


Audentes Therapeutics Inc.’s Current Ratio and Quick Ratio are 14.3 and 14.3 respectively. The Current Ratio and Quick Ratio of its competitor OncoCyte Corporation are 12.8 and 12.8 respectively. Audentes Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to OncoCyte Corporation.

Analyst Recommendations

The table given features the ratings and recommendations for Audentes Therapeutics Inc. and OncoCyte Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 1 0 2 2.67
OncoCyte Corporation 0 0 0 0.00

Audentes Therapeutics Inc. has a consensus target price of $33.33, and a 16.50% upside potential.

Insider & Institutional Ownership

Institutional investors held 0% of Audentes Therapeutics Inc. shares and 31.2% of OncoCyte Corporation shares. 1.3% are Audentes Therapeutics Inc.’s share held by insiders. On the other hand, insiders held about 23.9% of OncoCyte Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. -1.57% 1.22% 4.6% 62.23% 5.7% 82.55%
OncoCyte Corporation -10.61% -29.48% -57.14% -65.96% -33.21% 28.26%

For the past year Audentes Therapeutics Inc. was more bullish than OncoCyte Corporation.


Audentes Therapeutics Inc. beats OncoCyte Corporation on 7 of the 11 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.